Hengrui Medicine's SHR-4375 Injection Gets FDA Orphan Drug Designation for Pancreatic Cancer
Hengrui Medicine announced on July 27 that its product SHR-4375 injection has received orphan drug designation from the U. S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. Orphan drugs are those intended for the prevention, treatment, or diagnosis of rare diseases.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 60/100 and 80% confidence over a short term horizon.
Healthcare · 13.1
Pharmaceuticals
- Direction
- positive
- Intensity
- 60
- Confidence
- 80%
- Horizon
- Short term
Biotechnology
- Direction
- positive
- Intensity
- 60
- Confidence
- 80%
- Horizon
- Short term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.